Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

Fig. 1

a Global gDNA methylation pattern and prognosis of rGBM patients under POH inhaled therapy. The majority of rGBM patients (67%) presented with hypomethylated phenotype compared to hypermethylated group (33%, p < 0.0001). b Multiple comparison tests at 25 weeks confirm survival advantage to gDNA hypermethylated patients (median survival = 88 weeks) in comparison to hypomethylated rGBM survivors above 25 weeks (median survival = 44 weeks; d = 0.639)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us